Dendreon First Quarter Earnings Sneak Peek
Dendreon Corporation (NASDAQ:DNDN) will unveil its latest earnings on Monday, May 7, 2012. Dendreon is a biotechnology company that discovers, develops, and sells new therapeutics for cancer patients.
Dendreon Corporation Earnings Preview Cheat Sheet
Wall St. Earnings Expectations: The average estimate of analysts is for a loss of 65 cents per share, a narrower loss from the year-earlier quarter net loss of 77 cents. During the past three months, the average estimate has moved down from a loss of 52 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at a loss of 65 cents during the last month.
Past Earnings Performance: Last quarter, the company reported profit of 26 cents per share versus a mean estimate of net loss of. The company has beaten estimates for the past three quarters.
Investing Insights: What’s the Future of Microsoft’s Stock?
Wall St. Revenue Expectations: Analysts predict a rise of more than twofold in revenue from the year-earlier quarter to $81.2 million.
Analyst Ratings: Analysts seem relatively indifferent about Dendreon with 11 of 19 analysts surveyed maintaining a hold rating.
A Look Back: In the fourth quarter of the last fiscal year, the company swung to a profit of $38.1 million (27 cents a share) from a loss of $91.8 million (64 cents) a year earlier, beating analyst estimates. Revenue rose 708.4% to $202.1 million from $25 million.
Dendreon reported a profit last quarter, ending a three-quarter streak of loss. The company reported a loss of $147.1 million in the third quarter of the last fiscal year, a loss of $114.6 million in the second of the last fiscal year and a loss of $111.8 million in the first quarter of the last fiscal year.
Stock Price Performance: Between February 7, 2012 and May 3, 2012, the stock price fell $4.57 (-28.6%), from $15.96 to $11.39. The stock price saw one of its best stretches over the last year between May 16, 2011 and May 31, 2011, when shares rose for 11 straight days, increasing 15% (+$5.53) over that span. It saw one of its worst periods between July 21, 2011 and August 2, 2011 when shares fell for nine straight days, dropping 10.6% (-$4.15) over that span.
(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)
Don’t Miss These Additional Hot Stories: